A microRNA regulon that mediates endothelial recruitment by metastatic human breast cancer cells.
ABSTRACT: This SuperSeries is composed of the following subset Series: GSE23904: Gene expression profilling of poorly metastatic MDA cells and highly metastatic LM2 cells. GSE23905: miR-126 over-expression in highly metastatic LM2 breast cancer cells. Refer to individual Series
Metastatic progression of cancer is a complex and clinically daunting process. We previously identified a set of human microRNAs (miRNAs) that robustly suppress breast cancer metastasis to lung and bone and which display expression levels that predict human metastasis. Although these findings revealed miRNAs as suppressors of cell-autonomous metastatic phenotypes, the roles of non-coding RNAs in non-cell-autonomous cancer progression processes remain unknown. Here we reveal that endogenous miR-1 ...[more]
Project description:miR-126 were over-expressed using the miR-Vec system in highly metastatic LM2 cells. The LM2 cell line are described in detail in Minn et al. Nature 2005 This approach was used to conduct an unbiased search for specific miR-126 target genes in breast cancer cells. 4 Samples
Project description:Comparison of gene expression between the breast cancer cell line MDA-MB-231 and its highly metastatic deriviate LM2 cells (described in Minn et al., Nature 2005). Results hilghlights potential metastasis promoting and suppressing genes. Overall design: 4 Samples
Project description:Comparison of gene expression between the breast cancer cell line MDA-MB-231 and its highly metastatic deriviate LM2 cells (described in Minn et al., Nature 2005). Results hilghlights potential metastasis promoting and suppressing genes. 4 Samples
Project description:miR-126 were over-expressed using the miR-Vec system in highly metastatic LM2 cells. The LM2 cell line are described in detail in Minn et al. Nature 2005 This approach was used to conduct an unbiased search for specific miR-126 target genes in breast cancer cells. Overall design: 4 Samples
Project description:Human melanoma MeWo cells and their respective LM2 metastatic derivatives, generated through in vivo selection, were transcriptomically profiled in the context of miR-199a and miR-1908 gain- and loss-of-function in order to identify putative target genes for these miRNAs, MeWo cells and their respective LM2 metastatic derivatives in the context of miR-199a and miR-1908 gain- and loss-of-function
Project description:Next-generation sequencing has revolutionized cancer biology by accelerating the unbiased discovery of novel mutations across human cancers. Transforming such discoveries into a conceptual framework of cancer progression requires narrowing the vast number of mutations down to the driver elements, and further reducing these to mutations that govern cancer progression as opposed to tumor initiation. By integrating next-generation RNA-sequencing (RNA-seq) with in vivo selection, we devise an approach that identifies a series of novel recurrent non-synonymous amino acid mutations that are enriched in metastatic breast cancer cells and predicted to significantly alter protein function. These mutations, found in PANX1, RBFA, REST, KRIT1 and ZSWIM6, are detected at higher frequencies in the transcriptomes of two patients’ highly metastatic sub-lines relative to their poorly metastatic parental lines. We functionally characterize the cellular and molecular roles of one of these mutations—a nonsense alteration that yields a truncated pannexin-1 (PANX11-89) plasma membrane megachannel subunit—in metastatic progression. PANX11-89 interacts with full-length PANX1 and augments PANX1 channel activity to promote the survival of cancer cells as they are mechanically deformed. Protection from deformation-induced cell death requires PANX1 channels to release ATP, which acts as a cell autonomous survival signal during mechanical stress. Functional characterization of additional nonsense and missense PANX1 mutations detected in epithelial cancers of the colon, lung, and prostate reveals that these mutants also enhance PANX1-mediated ATP release. In vivo testing of one such truncating mutation detected in a metastatic colorectal tumor also enhances early survival, dissemination and liver metastatic colonization by human colon cancer cells. Finally, pharmacological inhibition of PANX1 inhibits breast cancer metastasis, implicating PANX1 as a novel therapeutic target in cancer. Our findings reveal that ATP release through mechanosensitive PANX1 channels enables cancer cells to overcome a major metastasis suppressive barrier—deformation-induced death in the microvasculature. To systematically identify base-pair mutations present in metastatic cells that may drive cancer progression, we performed whole-transcriptome RNA-sequencing (RNA-seq) of in vivo-selected, highly metastatic human breast cancer cell sub-lines, CN-LM1A and MDA-LM2, as well as the CN34 and MDA-MB-231 parental lines from which they were derived. To minimize the false positive rate and allow for subsequent statistical analysis, we sequenced biological replicates of each cell line. Mutations conferring enhanced metastatic capacity should be enriched in the transcriptomes of highly metastatic cells relative to their less metastatic parental populations.
Project description:This study investigates for the miRNAs that drive or regulates Renal Cell Carcinoma (RCC) metastatic progression using two different RCC cell lines, the metastatic (LM2 and LM1) and non-metastatic (SN12C). Overall design: The experiment is designed with three RCC cell lines one non-metastatic (SN12C) and two metastatic (LM1 and LM2). Each cell line has two biological replicates (exception SN12C has 3 replicates)